Premium
A Clinical Evaluation of Serum Placental Alkaline Phosphatase in Seminoma Patients
Author(s) -
JEPPSSON A.,
WAHREN B.,
STIGBRAND T.,
EDSMYR F.,
ANDERSSON L.
Publication year - 1983
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1983.tb07083.x
Subject(s) - placental alkaline phosphatase , seminoma , alkaline phosphatase , medicine , radioimmunoassay , antibody , gastroenterology , chemotherapy , biology , immunology , enzyme , biochemistry
Summary— Serum levels of placental alkaline phosphatase (PLAP) were measured in 100 patients with seminoma. A specific double antibody radioimmunoassay was used. PLAP was elevated for 9 out of 21 patients with primary tumours, to a mean of 53 μ gI I. Of the 12 cases with recurrent or metastatic growth, nine had raised PLAP. The sensitivity of PLAP determinations for primary and advanced disease was 55%. After successful treatment of seminoma, the PLAP level decreased. In a group of 68 patients with no evidence of disease, nine had slightly elevated serum PLAP. In many, but not all patients, serum PLAP parallelled the changes in tumour burden. In such patients and for follow‐up of treatment, PLAP might be used as a new marker for seminomatous disease.